EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells

Nutrition and Cancer

Volumn 66, Issue 4, 2014, Pages 636-644

  Zhou, Dong Hu ^a   Wang, Xuemin ^a   Feng, Qing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIGALLOCATECHIN GALLATE; HSA MICRORNA 125A 3P; HSA MICRORNA 98 5P; MICRORNA; PROTEIN P53; UNCLASSIFIED DRUG; CATECHIN; MIRN98 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER SIZE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; MOUSE; MTT ASSAY; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; XENOGRAFT; ANALOGS AND DERIVATIVES; BIOLOGY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CATECHIN; CELL LINE, TUMOR; CISPLATIN; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; TRANSFECTION; UP-REGULATION;

EID: 84899897735     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.894101     Document Type: Article

References (42)

1. Videtic GM: Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen? Cleve Clin J Med 79(Suppl 1), S32-S37, 2012.
2. Zamble DB and Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20, 435-439, 1995.
3. Galanski M: Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 1, 285-295, 2006.
4. Koberle B, Tomicic MT, Usanova S, and Kaina B: Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806, 172-182, 2010.
5. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7, 573-584, 2007.
6. Yang H, Landis-Piwowar K, Chan TH, and Dou QP: Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Curr Cancer Drug Targets 11, 296-306, 2011.
7. Shimizu M, Adachi S, Masuda M, Kozawa O, and Moriwaki H: Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res 55, 832-843, 2011.
8. Yang CS,Wang X, Lu G, and Picinich SC: Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9, 429-439, 2009.
9. Kim JW, Amin AR, and Shin DM: Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) 3, 900-909, 2010.
10. Yang CS and Wang H:Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res 55, 819-831, 2011.
11. Stearns ME and Wang M: Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl Oncol 4, 147-156, 2011.
12. Lecumberri E, Dupertuis YM, Miralbell R, and Pichard C: Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr 32, 894-903, 2013. doi: 10.1016/j.clnu.2013.03. 008
13. Yunos NM, Beale P, Yu JQ, and Huq F: Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res 31, 1131-1140, 2011.
14. Shervington A, Pawar V, Menon S, Thakkar D, and Patel R: The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol Biol Rep 36, 1181-1186, 2009.
15. Chan MM, Soprano KJ, Weinstein K, and Fong D: Epigallocatechin-3- gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207, 389-396, 2006.
16. El-Mowafy AM, Salem HA, Al-Gayyar MM, El-Mesery ME, and El-Azab MF: Evaluation of renal protective effects of the green-tea (EGCG) and red grape resveratrol: role of oxidative stress and inflammatory cytokines. Nat Prod Res 25, 850-856, 2011.
17. El-MowafyAM, Al-Gayyar MM, Salem HA, El-MeseryME, and Darweish MM: Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 17, 1067-1075, 2010.
18. Schmitt NC, Rubel EW, and Nathanson NM: Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci 29, 3843-3851, 2009.
19. Shen J, Stass SA, and Jiang F: MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329, 125-136, 2013.
20. JanssonMD and Lund AH: MicroRNA and cancer. Mol Oncol 6, 590-610, 2012.
21. Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353, 1768-1771, 2005.
22. Li C, Hashimi SM, Good DA, Cao S, Duan W, et al.: Apoptosis and microRNAaberrations in cancer. Clin Exp Pharmacol Physiol 39, 739-746, 2012.
23. Tsang WP and Kwok TT: Epigallocatechin gallate up-regulation of miR- 16 and induction of apoptosis in human cancer cells. J Nutr Biochem 21, 140-146, 2010.
24. Wang H, Bian S, and Yang CS: Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 32, 1881-1889, 2011.
25. Mazumder ME, Beale P, Chan C, Yu JQ, and Huq F: Epigallocatechin gallate acts synergistically in combinationwith cisplatin and designed transpalladiums in ovarian cancer cells. Anticancer Res 32, 4851-4860, 2012.
26. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, et al.: mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 9, 1080-1091, 2010.
27. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7, 1-9, 2008.
28. Kutuk O, Arisan ED, Tezil T, Shoshan MC, and Basaga H: Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 30, 1517-1527, 2009.
29. Zhang S, Zhang C, Li Y,Wang P, Yue Z, et al.: miR-98 regulates cisplatininduced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother 65, 436-442, 2011.
30. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, LindowM, et al.: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201, 2010.
31. Chen H, Landen CN, Li Y, Alvarez RD, and Tollefsbol TO: Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 downregulation. Exp Cell Res 319, 697-706, 2013.
32. De Amicis F, Perri A, Vizza D, Russo A, Panno ML, et al.: Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol 228, 2054-2062, 2013.
33. Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, et al.: Downregulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol 40, 1477-1482, 2012.
34. Huang B, Luo W, Sun L, Zhang Q, Jiang L, et al.: MiRNA-125a-3p is a negative regulator of the RhoA-actomyosin pathway in A549 cells. Int J Oncol 42, 1734-1742, 2013.
35. Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, et al.: Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. Bmc Cancer 10, 318, 2010.
36. Ninio-Many L, Grossman H, Shomron N, Chuderland D, and Shalgi R: microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn. J Cell Sci 126, 2867-2876, 2013.
37. Suganuma M, Saha A, and Fujiki H: New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 102, 317-323, 2011.
38. Farabegoli F, Papi A, Bartolini G, Ostan R, and Orlandi M: (-)- Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17, 356-362, 2010.
39. Farabegoli F, Barbi C, Lambertini E, and Piva R: (-)-Epigallocatechin-3- gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev 31, 499-504, 2007.
40. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, and Liao S: Suppression of and rogen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 275, 86-92, 2009.
41. Bannerman B, Xu L, Jones M, Tsu C, Yu J, et al.: Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 68, 1145-1154, 2011.
42. Ge J, Tan BX, Chen Y, Yang L, Peng XC, et al.: Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J MolMed (Berl) 89, 595-602, 2011.